A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 117



Geoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, Hatim Husain, Daniel B Costa, Philip Tracy, Nora Feeney, Lynette M Sholl, Suzanne E Dahlberg, Amanda J Redig, David J Kwiatkowski, Michael S Rabin, Cloud P Paweletz, Kenneth S Thress, Pasi A Jänne. JAMA Oncol 2018
Times Cited: 264




List of shared articles



Times cited

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
0

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova,[...]. Clin Cancer Res 2021
19

EGFR-mutant NSCLC: emerging novel drugs.
Lingyun Ye, Xiaoxia Chen, Fei Zhou. Curr Opin Oncol 2021
1

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.
Julia Lai-Kwon, Crescens Tiu, Abhijit Pal, Sachin Khurana, Anna Minchom. Crit Rev Oncol Hematol 2021
3

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient.
Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, João Victor Machado Alessi, Andrea Kazumi Shimada, José Flávio Gomes Marin, Anamaria Aranha Camargo,[...]. NPJ Precis Oncol 2021
2

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.
Aaron C Tan, Tracy J Loh, Xue Lin Kwang, Gek San Tan, Kiat Hon Lim, Daniel S W Tan. Lung Cancer (Auckl) 2021
0

When the MET receptor kicks in to resist targeted therapies.
Marie Fernandes, Philippe Jamme, Alexis B Cortot, Zoulika Kherrouche, David Tulasne. Oncogene 2021
0

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Ryoji Kato, Hidetoshi Hayashi, Kazuko Sakai, Shinichiro Suzuki, Koji Haratani, Takayuki Takahama, Junko Tanizaki, Yoshikane Nonagase, Kaoru Tanaka, Takeshi Yoshida,[...]. Int J Clin Oncol 2021
1


Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer.
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park, Yeon-Sun Seong. Pharmaceuticals (Basel) 2021
0


Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller. Cancers (Basel) 2021
0

Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer.
V H F Lee, T S K Mok, Y Goto, V C C Hsue, L Yang, Y Jiang, D K C Leung, K S Lau, P Y Tse. Clin Oncol (R Coll Radiol) 2020
1


Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
92

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
41

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
G R Oxnard, J C-H Yang, H Yu, S-W Kim, H Saka, L Horn, K Goto, Y Ohe, H Mann, K S Thress,[...]. Ann Oncol 2020
86


MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
27

Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
19

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Yubo Wang, Panwen Tian, Lei Xia, Li Li, Rui Han, Mengxiao Zhu, Analyn Lizaso, Tian Qin, Min Li, Bing Yu,[...]. Lung Cancer 2020
5

Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs.
D Franceschini, S Rossi, M Loi, I Chiola, F Piccoli, F R Lutman, G Finocchiaro, L Toschi, A Santoro, M Scorsetti. Expert Rev Anticancer Ther 2020
0

The METeoric rise of MET in lung cancer.
Alex Friedlaender, Alexander Drilon, Giuseppe Luigi Banna, Solange Peters, Alfredo Addeo. Cancer 2020
7

Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study.
Jiang-Tao Cheng, Yi-Hui Yao, Yu-Er Gao, Shi-Ling Zhang, Hua-Jun Chen, Zhen Wang, Hong-Hong Yan, Qing Zhou, Hai-Yan Tu, Xu-Chao Zhang,[...]. Lung Cancer 2020
2

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.
Ayesha Murtuza, Ajaz Bulbul, John Paul Shen, Parissa Keshavarzian, Brian D Woodward, Fernando J Lopez-Diaz, Scott M Lippman, Hatim Husain. Cancer Res 2019
67

Update on emerging biomarkers in lung cancer.
Eric H Bernicker, Timothy Craig Allen, Phillip T Cagle. J Thorac Dis 2019
12


Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
Jordi Remon, Myung-Ju Ahn, Nicolas Girard, Melissa Johnson, Dong-Wan Kim, Gilberto Lopes, Rathi N Pillai, Benjamin Solomon, Guillermo Villacampa, Qing Zhou. J Thorac Oncol 2019
40